Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15896828 | 0.85 | GAA (0.47) | GAACYP2C9GFERALDH1A1SMN1; SMN2 | |
| SCHEMBL23587194 | 0.79 | GAA (0.42) | GAACYP2C9GFERALDH1A1SMN1; SMN2 | |
| SCHEMBL7993567 | 0.76 | SMN1; SMN2 (0.43) | GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL29339867 | 0.75 | GAA (0.39) | GAA | |
| SCHEMBL15694020 | 0.75 | GAA (0.39) | GAAALDH1A1 | |
| SCHEMBL12871802 | 0.74 | GAA (0.45) | GAACYP2C9GFERALDH1A1SMN1; SMN2 | |
| SCHEMBL13233140 | 0.73 | GAA (0.59) | GAACYP2C9GFERSMN1; SMN2 | |
| SCHEMBL26927492 | 0.72 | GAA (0.33) | GAAALDH1A1SMN1; SMN2ADCY10 | |
| SCHEMBL29339804 | 0.72 | GAA (0.37) | GAAADCY10 | |
| SCHEMBL28296214 | 0.71 | KMT2A (0.40) | GAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | GAA 673/4885CYP2C9 274/4885GFER 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.